FDG-PET imaging clearly predicts lung cancer patients' response to chemotherapyMay 09, 2007
RESTON, Va. -- An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients--provided by positron emission tomography (PET) imaging--can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.
"Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival," explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. "Although we studied a relatively small number of patients--and our results should be interpreted with caution--it is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile," he said. "The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment," explained Nahmias. "Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach," added the co-author of "Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT."
Non-small cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with non-small cell lung cancer, current treatments do not cure the cancer.
"With non-small cell lung cancer--since the relatively modest increase in survival must be balanced against the toxicity of the chemotherapeutic treatment--the case for monitoring therapeutic response is especially compelling," said Nahmias. "To assess the response to chemotherapy in patients with advanced non-small cell lung cancer, all of the studies published thus far have evaluated the patients at one, or at most two, time points after the initiation of chemotherapy," said Nahmias. "In our study, we evaluated 15 patients weekly--for seven weeks--as they started their chemotherapy regiment. In spite of the persuasive findings of several studies investigating PET for monitoring response to cancer therapy, until now no published reports have clearly demonstrated that PET results were used to alter treatment," he noted.
PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the body's chemistry, metabolic activity and body function.
"Our result--that PET studies one and three weeks after initiation of cancer therapy can predict success or failure of the therapy--should be validated in a larger study in which patients are enrolled with the intention of applying it in patient management," said Nahmias. He added, "I am forever grateful to all the patients who came back week after week to undergo our PET scans."
Media representatives: To obtain a copy of this article, please contact Maryann Verrillo by phone at (703) 652-6773 or send an e-mail to firstname.lastname@example.org. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org. Print copies can be obtained by contacting the SNM Service Center, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail email@example.com; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.
About SNM--Advancing Molecular Imaging and TherapySNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (the Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced--and continue to explore--biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.
Society of Nuclear Medicine
Related Lung Cancer Articles:
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.
Related Lung Cancer Reading:
How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)
Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter... View Details
Lung Cancer: Your Questions, Expert Answers
by Joan H. Schiller (Author)
No one with lung cancer needs to be alone in their fight against this disease. Lung Cancer: Your Questions, Expert Answers, Fourth Edition guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor's and patient's point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through Lung Cancer: Your Questions, Expert Answers, Fourth Edition, expert authors use their experiences with patients to provide support and hope to the tens of... View Details
Lung Cancer: From Diagnosis to Treatment
by Walter Scott MD (Author)
According to the American Cancer Society, nearly 220,000 Americans are diagnosed with lung cancer annually. It accounts for nearly 15 percent of all newly diagnosed cancers. If you've been diagnosed, you probably have many questions about the nature of the disease and your treatment options.Walter J. Scott, M.D., has treated thousands of lung cancer patients who have navigated this overwhelming maze of medical tests and procedures. In Lung Cancer: From Diagnosis to Treatment, Dr. Scott helps you understand the process—from getting a diagnosis to going through treatment. He explains... View Details
100 Questions & Answers About Lung Cancer (100 Questions and Answers)
by Joan H. Schiller (Author), Amy Cipau (Author)
No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Third Edition, guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor's and patient's point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Third Edition, expert authors use their experiences with patients to provide support and hope to the tens of... View Details
You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)
Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions.
This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the... View Details
Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management (Current Multidisciplinary Oncology)
by Kemp H. Kernstine MD PhD (Editor), Karen L. Reckamp MD MS (Editor), Charles R. Thomas Jr. MD (Editor)
Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the... View Details
Lung Cancer: A Multidisciplinary Approach
by Alison Leary (Editor)
Lung Cancer: A Multidisciplinary Approach provides clinicians with a comprehensive text that can be used when caring for patients with lung cancer throughout the entire patient journey. This edited collection explores the aetiology of lung cancer; mesothelioma; the range of available treatments, including chemotherapy and radiotherapy; surgical care; supportive and end-of-life care; quality-of-life issues; and the role of the nurse within the multidisciplinary team.A comprehensive, evidence-based guide to lung cancer Illustrative case studies used throughout Contributions from... View Details
The ABCs of Lung Cancer: for Patients and Advocates
by Dusty Joy Donaldson (Author), Kimberly D. Lester (Author), Kimberly D. Lester (Illustrator)
Learn valuable lessons from a longtime lung cancer survivor’s own journey The ABCs of Lung Cancer is a practical, easy-to-read guide for lung cancer patients and the people who care for and about them. Written by an 11-year lung cancer survivor and her daughter, the authors provide useful tips for dealing with and preventing lung cancer, some anecdotes about their own experiences, and, most of all, hope. Structured logically from A–Z, The ABCs of Lung Cancer gives frank advice that is easy to digest, despite the serious topic. Each segment offers insight garnered from the authors’ more... View Details
Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope
by Bonnie J. Addario (Author), MD, PhD, Shane P. Dormady (Author), RN, MSN, CPHQ, Eileen Johnson (Author), RN, MBA, Alicia Sable-Hunt (Author), Danielle Hicks (Editor), MD, Paul Hesketh (Editor), MD, Robert Sinha (Editor), MD, PhD, D. Ross Camidge (Editor), MD, Elizabeth A. David (Editor), MD, Lisa Boohar (Editor), MD, David R. Gandara (Editor), PhD, Guneet Walia (Editor), Inc., Sheila Von Driska?White Space (Editor)
Navigating Lung Cancer 360 Degrees of Hope is the most comprehensive guidebook for surviving lung cancer. Inside each latest edition you will get the most up-to-date navigation tools on the diagnosis process, lung cancer staging, treatment options, clinical trials, living with lung cancer, financing your care, hope for surviving lung cancer, and more. Written by survivor Bonnie J. Addario and the leading experts in lung cancer with one goal: to turn lung cancer into a manageable and survival disease. View Details
Johns Hopkins Patients' Guide to Lung Cancer
by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author)
Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow "how to" guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment. View Details